Press Releases Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris Other stock markets 09:05:09 26/04/2024 pm IST			5-day change	1st Jan Change
14.82 ^EUR	+0.54%		+4.66%	+50.92%

11/04	Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	MT
08/04	Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abivax publishes financial reports with the French and U.S. securities regulatory agencies	08/04	AQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies	06/04	EQ
Abivax reports 2023 financial results and operational update	02/04	EQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)	14/02	AQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)	13/02	EQ
Abivax appoints Ana Sharma as Vice President, Global Head of Quality	07/02	EQ
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease	05/02	AQ
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease	02/02	EQ
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024	24/01	EQ
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months	22/01	EQ
Abivax 2024 Financial Communication Calendar	04/01	EQ
Abivax announces the resumption of its liquidity contract	21/11	EQ
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference	14/11	EQ
Abivax Announces $235.8 Million IPO	27/23/27	AQ
Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market	25/23/25	EQ
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market	23/23/23	AQ
Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris	23/23/23	AQ
Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris	23/23/23	AQ
Abivax announces trading resumption of its ordinary shares on Euronext Paris	20/23/20	EQ
Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market	20/23/20	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Abivax

Equities

ABVX

FR0012333284

Press Releases

Filters